XML 72 R60.htm IDEA: XBRL DOCUMENT v3.22.4
FAIR VALUE DISCLOSURES - Level 3 (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Nov. 19, 2021
USD ($)
Changes in contingent consideration      
Level 3 liability, beginning balance $ 31,000    
Initial valuation   $ 30,800  
Measurement period adjustment 300    
Change in fair value $ 3,758 $ 200  
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability  
Level 3 liability, ending balance $ 35,058 $ 31,000  
Discount rate | Profit-based milestone payments      
Unobservable inputs 13.0    
Discount rate | Product development-based milestone payments      
Unobservable inputs 8.8    
Probability of payment | Product development-based milestone payments      
Unobservable inputs 95.0    
BioSante Pharmaceuticals | Discount rate      
Unobservable inputs 15    
Novitium      
Additional contingent consideration $ 46,500   $ 46,500